Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration rejected the drugmaker's bladder cancer treatment.

The company said it was considering a new smaller study for the drug, apaziquone, that would replace the ongoing late-stage study in which patient enrolment has been stopped.

More on this...